SL
Siren LLC Portfolio holdings
AUM
$1.93B
This Quarter Return
-13.7%
1 Year Return
+118.08%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$1.77B
AUM Growth
+$1.77B
(-22%)
Cap. Flow
-$54.5M
Cap. Flow
% of AUM
-3.08%
Top 10 Holdings %
Top 10 Hldgs %
50.37%
Holding
140
New
23
Increased
28
Reduced
41
Closed
24
Top Buys
| 1 |
BPMC
Blueprint Medicines
BPMC
|
$64.3M |
| 2 |
Disc Medicine
IRON
|
$53.2M |
| 3 |
Soleno Therapeutics
SLNO
|
$26.8M |
| 4 |
Edgewise Therapeutics
EWTX
|
$21.2M |
| 5 |
Rhythm Pharmaceuticals
RYTM
|
$14.7M |
Top Sells
| 1 |
argenx
ARGX
|
$70.8M |
| 2 |
KLRS
Kalaris Therapeutics, Inc. Common Stock
KLRS
|
$50.7M |
| 3 |
SWTX
SpringWorks Therapeutics
SWTX
|
$49.8M |
| 4 |
ONC
BeOne Medicines Ltd. American Depositary Shares
ONC
|
$42.2M |
| 5 |
Madrigal Pharmaceuticals
MDGL
|
$38.9M |
Sector Composition
| 1 | Healthcare | 89.75% |
| 2 | Technology | 5.2% |
| 3 | Communication Services | 2.41% |
| 4 | Consumer Discretionary | 1.21% |
| 5 | Real Estate | 0.81% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Scholar Rock
SRRK
$3.14B
| $297M | 16.78% | 9,250,005 | – | – |
|
|
ONC
2
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.4B
| $136M | 7.66% | 498,689 -155,032 | -24% | -$42.2M |
|
3
Kymera Therapeutics
KYMR
$2.95B
| $88.7M | 5% | 3,240,313 +270,580 | +9% | +$7.41M |
|
|
BPMC
4
DELISTED
Blueprint Medicines
BPMC
| $64.3M | 3.63% | +726,167 | New | +$64.3M |
|
5
Crinetics Pharmaceuticals
CRNX
$2.92B
| $56.6M | 3.19% | 1,688,611 +78,959 | +5% | +$2.65M |
|
6
Apellis Pharmaceuticals
APLS
$3.48B
| $56.4M | 3.18% | 2,578,396 -237,862 | -8% | -$5.2M |
|
|
7
Disc Medicine
IRON
$2.07B
| $53.2M | 3% | +1,071,865 | New | +$53.2M |
|
|
8
Soleno Therapeutics
SLNO
$3.6B
| $52M | 2.93% | 727,337 +375,519 | +107% | +$26.8M |
|
9
Ascendis Pharma
ASND
$11.8B
| $44.8M | 2.53% | 287,366 -9,955 | -3% | -$1.55M |
|
10
Merus
MRUS
$4.98B
| $43.9M | 2.48% | 1,043,467 +259,055 | +33% | +$10.9M |
|
|
BCAX
11
Bicara Therapeutics Inc. Common Stock
BCAX
$651M
| $42.6M | 2.4% | 3,267,083 -5,744 | -0.2% | -$74.8K |
|
|
CNTA
12
Centessa Pharmaceuticals
CNTA
$2.25B
| $42.6M | 2.4% | 2,960,029 -44,648 | -1% | -$642K |
|
13
NewAmsterdam Pharma
NAMS
$2.71B
| $39.1M | 2.21% | 1,912,030 -183,608 | -9% | -$3.76M |
|
|
14
Edgewise Therapeutics
EWTX
$1.51B
| $37.3M | 2.11% | 1,696,444 +962,101 | +131% | +$21.2M |
|
15
Arrowhead Research
ARWR
$3.05B
| $34M | 1.92% | 2,669,880 -231,801 | -8% | -$2.95M |
|
16
Avidity Biosciences
RNA
$5.99B
| $32.8M | 1.85% | 1,110,610 -16,685 | -1% | -$493K |
|
17
Wave Life Sciences
WVE
$1.53B
| $29.9M | 1.68% | 3,696,322 -54,169 | -1% | -$438K |
|
18
Taboola.com
TBLA
$991M
| $29.4M | 1.66% | 9,969,495 | – | – |
|
19
Dyne Therapeutics
DYN
$1.92B
| $28.4M | 1.6% | 2,717,987 +1,370,531 | +102% | +$14.3M |
|
20
Solid Biosciences
SLDB
$427M
| $27.4M | 1.55% | 7,415,905 +3,666,864 | +98% | +$13.6M |
|
21
Xenon Pharmaceuticals
XENE
$2.98B
| $24.6M | 1.39% | 732,761 -11,008 | -1% | -$369K |
|
22
Apogee Therapeutics
APGE
$2.17B
| $22.2M | 1.25% | 594,994 -152,331 | -20% | -$5.69M |
|
23
Revolution Medicines
RVMD
$7.1B
| $19.9M | 1.12% | 563,755 -7,793 | -1% | -$276K |
|
24
Trevi Therapeutics
TRVI
$883M
| $18M | 1.02% | 2,863,793 -42,267 | -1% | -$266K |
|
25
Vera Therapeutics
VERA
$1.38B
| $17.9M | 1.01% | 747,216 -11,249 | -1% | -$270K |
|